Ninety day survival outcomes in covid-19 ards trial of remestemcel-l presented at isct meeting on advances in cell & gene therapies for lung diseases

New york, july 18, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-l in ventilator-dependent covid-19 patients with moderate/severe acute respiratory distress syndrome (ards) at an invited presentation on july 17 to the international society for cell & gene therapy (isct) scientific signatures series on cell and gene therapies in lung diseases and critical illnesses. the results showed that two doses of remestemcel-l at days 3-5 conferred durable survival benefit through at least 90 days in the pre-specified subgroup of patients under age 65.
MESO Ratings Summary
MESO Quant Ranking